imipenem, anhydrous has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghavidel, M; Ghazvini, K; Kabiri, M; Khaksari, MN; Khoshbakht, R; Mousavi, SM; Neshani, A; Sadrzadeh, SM | 1 |
| Jarčuška, P; Porubčin, Š; Rovňáková, A; Zahornacký, O | 1 |
| Abdel-Moneim, AS; Al Yami, MR; Alghamdi, AN; Alghamdi, RK; Alharthi, AA; Almakki, RA; Alnemari, AA; Alsalmi, NM; Alwagdani, AA; Kadry, DY; Mahfouz, MEM; Osman, AS | 1 |
| Chen, DG; Kong, DP; Su, L; Tu, Y; Wang, ZB; Zhang, CX; Zhang, WN; Zhuang, CL | 1 |
4 other study(ies) available for imipenem, anhydrous and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Assessment of antibiotic resistance changes during the Covid-19 pandemic in northeast of Iran during 2020-2022: an epidemiological study.
Topics: Acinetobacter baumannii; Ampicillin; Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; COVID-19; Drug Resistance, Bacterial; Escherichia coli; Humans; Imipenem; Iran; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pandemics; Pseudomonas aeruginosa | 2022 |
[Imipenem-cilastatin-relebactam used to treat ventilator-associated pneumonia developing after infection with SARS-CoV-2].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin, Imipenem Drug Combination; COVID-19; Humans; Imipenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; SARS-CoV-2 | 2022 |
Comparison of Different Antiviral Regimens in the Treatment of Patients with Severe COVID-19: A Retrospective Cohort.
Topics: Antiviral Agents; COVID-19; Humans; Imipenem; Linezolid; Oseltamivir; Retrospective Studies; SARS-CoV-2 | 2023 |
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents.
Topics: Acute Lung Injury; Animals; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Repositioning; Guanine; Humans; Imipenem; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Pandemics; Pneumonia, Viral; Tumor Necrosis Factor-alpha | 2020 |